Meritus Medical Center INC
Meritus Medical Center INC was paid $3.41M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is G0378, Hospital observation service, per hour — 39% of everything it billed.
HAGERSTOWN, MD 21742
Next to other General Acute Care Hospital providers in Maryland
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,229 | $125K | |
| 2019 | 23,073 | $282K | |
| 2020 | 18,841 | $592K | |
| 2021 | 26,580 | $887K | |
| 2022 | 23,113 | $644K | |
| 2023 | 19,781 | $552K | |
| 2024incomplete | 13,981 | $333K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 39% | 2,540 | 2,222 | $1.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 9,195 | 7,883 | $708K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 8,860 | 7,613 | $687K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.8% | 2,544 | 2,219 | $164K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 1,376 | 393 | $105K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 1,363 | 1,199 | $75K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 1.3% | 1,427 | 898 | $43K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 1,799 | 1,562 | $42K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 515 | 295 | $41K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,860 | 1,764 | $18K |
| 80053 | Comprehensive metabolic panel | <1% | 12,662 | 10,051 | $15K |
| 85027 | <1% | 11,948 | 9,345 | $13K |
85 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,259 | $12K |
| J2704 | Injection, propofol, 10 mg | <1% | 657 | $11K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,941 | $11K |
| 84484 | <1% | 7,673 | $10K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 90 | $9K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 433 | $9K |
| 84702 | <1% | 1,958 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,660 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,097 | $6K |
| 93971 | <1% | 84 | $6K | |
| 87040 | <1% | 1,388 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,434 | $6K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,298 | $6K |
| 83690 | <1% | 4,304 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,679 | $4K |
| 80306 | <1% | 1,195 | $4K | |
| 81001 | <1% | 4,644 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 760 | $3K |
| 82948 | <1% | 5,452 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 795 | $3K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 627 | $3K |
| 83735 | <1% | 2,116 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,035 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 92 | $2K |
| 85610 | <1% | 2,213 | $2K | |
| 81003 | <1% | 2,825 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,506 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,986 | $1K |
| 73564 | <1% | 74 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 835 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,886 | $1K |
| 90715 | <1% | 25 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 89 | $1K |
| 85379 | <1% | 880 | $1K | |
| 83605 | <1% | 2,121 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 265 | $906.72 |
| 83880 | <1% | 1,367 | $866.75 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 42 | $808.19 |
| 90839 | <1% | 93 | $517.03 | |
| 85730 | <1% | 1,310 | $493.83 | |
| 86850 | <1% | 675 | $461.50 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 133 | $382.21 |
| 73030 | <1% | 47 | $332.10 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 18 | $311.25 |
| 73630 | <1% | 28 | $283.52 | |
| 73502 | <1% | 13 | $254.72 | |
| 87428 | <1% | 660 | $165.16 | |
| 86901 | <1% | 675 | $164.85 | |
| 86900 | <1% | 674 | $160.48 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 175 | $143.55 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 71 | $132.38 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 109 | $114.51 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 262 | $113.92 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 296 | $109.23 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $98.43 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 332 | $93.35 |
| 87186 | <1% | 340 | $89.69 | |
| 94799 | <1% | 421 | $77.43 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 125 | $70.19 |
| 80076 | <1% | 243 | $66.83 | |
| 90837 | Psychotherapy session, about an hour | <1% | 13 | $63.59 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 279 | $39.11 |
| 87641 | <1% | 62 | $39.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 121 | $35.51 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 128 | $34.92 |
| 82550 | <1% | 16 | $24.87 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 546 | $22.35 |
| 87077 | <1% | 88 | $17.63 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 169 | $12.48 |
| 86140 | <1% | 79 | $3.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 137 | $0.42 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 70 | $0.30 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 58 | $0.25 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 61 | $0.22 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 48 | $0.19 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 19 | $0.06 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 13 | $0.04 |
| A9270 | Non-covered item or service | 0% | 1,550 | $0.00 |
| 97597 | 0% | 240 | $0.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 130 | $0.00 |
| 80320 | 0% | 57 | $0.00 | |
| 94760 | 0% | 15 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 86 | $0.00 |
| 87631 | 0% | 12 | $0.00 | |
| 80061 | Lipid panel | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Medical Practices of Antietam, LLC | Hagerstown, MD | $20.56M |
| Meritus Medical Laboratory LLC | Hagerstown, MD | $12.14M |
| Brook Lane Behavioral Services, INC. | Frederick, MD | $5.59M |
| Meritus Urgent Care, LLC | Hagerstown, MD | $4.93M |
| Brook Lane Behavioral Services, INC. | Hagerstown, MD | $3.12M |
| Meritus Medical Center INC | Hagerstown, MD | $1.47M |
| Meritus Enterprises,inc. | Hagerstown, MD | $1.28M |
| Meritus Medical Center INC | Hagerstown, MD | $1.18M |
| Meritus Medical Center INC | Hagerstown, MD | $968K |
| Meritus Medical Center INC | Hagerstown, MD | $828K |
| Meritus Medical Center INC | Hagerstown, MD | $517K |
| Meritus Medical Center INC | Hagerstown, MD | $60K |
| Meritus Medical Center INC | Hagerstown, MD | $49K |
| Meritus Medical Center INC | Hagerstown, MD | $17K |
| Meritus Medical Center INC | Hagerstown, MD | $2K |
| Meritus Medical Center, INC. | Hagerstown, MD | $796.87 |
| Meritus Urgent Care LLC | Hagerstown, MD | $92.10 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.